Table 3.

Results of pre-specified exploratory and post-hoc analyses. Unless specified otherwise, all analyses are adjusted for stratification variables. Abbreviations: SITS-MOST–Safe Implementation of Thrombolysis in Stroke-Monitoring Study. Abbreviations: CrI–credible interval, CI–confidence interval.

	Control rt-PA-alone N=29	Low-Dose Argatroban + rt-PA N=30	High-Dose Argatroban + rt-PA N=31	Low + High-Dose Argatroban + rt-PA N=61
PRESPECIFIED EXPLORATORY ANALYSIS
mRS 0–1 at 90-days adjusted for stratification variables, age and NIHSS
RR (95% CrI), probability RR>1.0	–	1.17 (0.56, 2.4), 0.66	1.07 (0.53, 2.16), 0.58	1.18 (0.59, 2.43), 0.67
POST HOC ANALYSES
mRS 0–1 at 90-days
1) * Ordinal Logistic Regression OR (95% CI), p-value	–	1.23 (0.49, 3.07), 0.66	2.03 (0.8, 5.1), 0.13	1.58 (0.71, 3.50), 0.26
2) * Poisson Regression RR (95% CI), p-value	–	1.50 (0.64, 3.49), 0.35	1.63 (0.72, 3.72), 0.24	1.57 (0.74, 3.33), 0.24
Symptomatic Intracerebral Hemorrhage
3) Intention To Treat (ITT) N(%), 95% CI	3(10), 2.2–27.4	4(13), 3.8–30.7	2(7), 0.8–21.4	6(10), 3.7–20.2
* RR (95% CI), p-value	–	1.27 (0.32-5.1), 0.74	0.60 (0.11-3.41), 0.56	0.93 (0.25-3.48), 0.91
As Treated N(%), 95% CI	4(13), 3.8–30.7	4(13), 3.8–30.7	1(3), 0.1–17.2	5(8), 2.8–18.4
* RR (95% CI), p-value	–	0.98 (0.28–3.47), 0.97	0.24 (0.03–2.07), 0.19	0.60 (0.17–2.11), 0.43
SITS-MOST Definition (ITT) N(%), 95% CI	0	1(3), 0.1–17.2	2(7), 0.8–21.4	3(5), 1.0–13.7
SITS-MOST Definition (As Treated) N(%), 95% CI	1(3), 0.1–17.2	1(3), 0.1–17.2	1(3), 0.1–17.2	2(3), 0.4–11.5
4) †Neutral Prior Bayesian RR (95% CrI), probability RR>1.0	–	1.17 (0.48, 2.75), 0.63	0.82 (0.33, 2.0), 0.34	0.98 (0.42, 2.4), 0.48

^*Frequentist Poisson Regression.

^†Neutral Prior: RR=1.0 and 95% predictive interval: 0.33–3.0.